dalteparin has been researched along with Ischemia in 28 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using a computer algorithm 284 patients with lower limb ischemia, most with pre-operative ischemic ulceration or partial gangrene, from 12 hospitals were randomised, after PABG, to 5000 IU dalteparin or placebo injections once daily for 3 months." | 9.11 | Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial. ( Drott, C; Gelin, J; Groth, O; Hensäter, M; Jensen, N; Jivegård, L; Johansson, G; Konrad, P; Lindberg, B; Lindhagen, A; Lundqvist, B; Oden, A; Ortenwall, P; Smith, L; Stenberg, B; Thornell, E; Wingren, U, 2005) |
| "Wistar-albino rats (weighing 350-400 g) were divided into four groups as follows: Sham-Control (Group 1), Control-Saline+ischemia/reperfusion (Group 2), Ticagrelor+ischemia/reperfusion (Group 3), and Enoxaparin+ischemia/reperfusion (Group 4)." | 8.02 | Changes in cardiac cells due to ticagrelor and enoxaparin in a rat ischemia/reperfusion model. ( Baris, O; Fındık, O; Kunt, AT; Rencber, SF; Sarihan, KK; Yazir, Y; Yilmaz, MY, 2021) |
| "Although congenital afibrinogenemia is a rare autosomal recessive bleeding disorder, it can be more frequently encountered in countries where consanguineous marriages are common." | 7.81 | A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations. ( Işik, B; Karakukcu, M; Mutlu, FT; Ozdemir, MA; Patiroglu, T; Unal, E; Yilmaz, E, 2015) |
| "After successful PTA, 275 patients with symptomatic peripheral arterial disease (claudication or critical limb ischemia) and femoropopliteal obstructions were randomized to receive either 2500 IU of dalteparin subcutaneously for 3 months plus 100 mg of aspirin daily (n = 137), or 100 mg aspirin daily alone (n = 138)." | 5.12 | Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. ( Amann-Vesti, BR; Banyai, M; Koppensteiner, R; Meier, T; Pfammatter, T; Rousson, V; Spring, S; van der Loo, B, 2006) |
| "Using a computer algorithm 284 patients with lower limb ischemia, most with pre-operative ischemic ulceration or partial gangrene, from 12 hospitals were randomised, after PABG, to 5000 IU dalteparin or placebo injections once daily for 3 months." | 5.11 | Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial. ( Drott, C; Gelin, J; Groth, O; Hensäter, M; Jensen, N; Jivegård, L; Johansson, G; Konrad, P; Lindberg, B; Lindhagen, A; Lundqvist, B; Oden, A; Ortenwall, P; Smith, L; Stenberg, B; Thornell, E; Wingren, U, 2005) |
| "Wistar-albino rats (weighing 350-400 g) were divided into four groups as follows: Sham-Control (Group 1), Control-Saline+ischemia/reperfusion (Group 2), Ticagrelor+ischemia/reperfusion (Group 3), and Enoxaparin+ischemia/reperfusion (Group 4)." | 4.02 | Changes in cardiac cells due to ticagrelor and enoxaparin in a rat ischemia/reperfusion model. ( Baris, O; Fındık, O; Kunt, AT; Rencber, SF; Sarihan, KK; Yazir, Y; Yilmaz, MY, 2021) |
| " Conservative treatment included: (a) weight-adjusted bemiparin plus six hours/day intravenous iloprost for 28 days, (b) aspirin (100 mg/day) plus cilostazol (100 mg twice/day) after discharge, and (c) strict recommendations/monitoring for smoking cessation." | 3.85 | Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia. ( Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I, 2017) |
| "Although congenital afibrinogenemia is a rare autosomal recessive bleeding disorder, it can be more frequently encountered in countries where consanguineous marriages are common." | 3.81 | A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations. ( Işik, B; Karakukcu, M; Mutlu, FT; Ozdemir, MA; Patiroglu, T; Unal, E; Yilmaz, E, 2015) |
| "Patients with stroke are at substantial risk of thromboembolic complications and therefore require antithrombotic prophylaxis." | 2.72 | Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. ( Brom, J; Csányi, A; Diener, HC; Harenberg, J; Klingelhöfer, J; Koppenhagen, K; Landgraf, H; Rektor, I; Ringelstein, EB; Schneider, D; von Kummer, R; Weidinger, G, 2006) |
| "BACKGROUND Coronavirus disease 2019 (COVID-19) has a tremendous impact on the respiratory tract." | 1.72 | A Patient-Tailored Approach to Management of Acute Limb Ischemia in Patients with COVID-19: A Case Series. ( AlGhofili, H; Alhumaid, A; Aljabri, B; Altoijry, A; Iqbal, K, 2022) |
| "Ergotism is an ischaemic complication due to vasoconstriction throughout the body due to ingestion of ergotamine." | 1.48 | Headache in an HIV-Positive Patient: Dangerous Interaction. ( Garner, O; Iardino, A; Lorusso, G; Lotta, F, 2018) |
| " Chronic administration of the drugs resulted in stable anticoagulation in all animals throughout the experiment." | 1.33 | Early in vivo anticoagulation inhibits the angiogenic response following hindlimb ischemia in a rodent model. ( Annichino-Bizzacchi, JM; Arruda, VR; De Paula, EV; Guillaumon, AT; Machado, TF; Nascimento, MC; Ozelo, MC; Ramos, CD, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 14 (50.00) | 24.3611 |
| 2020's | 4 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Stammler, F | 1 |
| Grau, C | 1 |
| Eckstein, HH | 1 |
| Biesek, D | 1 |
| Ksiazkiewicz, B | 1 |
| Wanat-Słupska, E | 1 |
| Mazzone, A | 1 |
| Giani, L | 1 |
| Faggioli, P | 1 |
| Pichini, S | 1 |
| Pacifici, R | 1 |
| Ertem, K | 1 |
| Kobza, II | 1 |
| Galyfos, G | 1 |
| Kerasidis, S | 1 |
| Kastrisios, G | 1 |
| Giannakakis, S | 1 |
| Sachmpazidis, I | 1 |
| Anastasiadou, C | 1 |
| Geropapas, G | 1 |
| Papapetrou, A | 1 |
| Papacharalampous, G | 1 |
| Maltezos, C | 1 |
| Fındık, O | 1 |
| Baris, O | 1 |
| Yazir, Y | 1 |
| Yilmaz, MY | 1 |
| Rencber, SF | 1 |
| Sarihan, KK | 1 |
| Kunt, AT | 1 |
| Alhumaid, A | 1 |
| Altoijry, A | 1 |
| Aljabri, B | 1 |
| Iqbal, K | 1 |
| AlGhofili, H | 1 |
| Dogan Ozcil, M | 1 |
| Ozcan, O | 1 |
| Hakverdi, S | 1 |
| Bayraktar, HS | 1 |
| Dirican, E | 1 |
| Kacmaz, F | 1 |
| Bostancı, MS | 1 |
| Budak, O | 1 |
| Çakiroğlu, H | 1 |
| Köse, O | 1 |
| Durmaz, Ö | 1 |
| Cokluk, E | 1 |
| Kohlert, S | 1 |
| McLean, L | 1 |
| Scarvelis, D | 1 |
| Thompson, C | 1 |
| Iardino, A | 1 |
| Garner, O | 1 |
| Lorusso, G | 1 |
| Lotta, F | 1 |
| Kemik, O | 1 |
| Adas, G | 1 |
| Arikan, S | 1 |
| Gurluler, E | 1 |
| Dogan, Y | 1 |
| Toklu, AS | 1 |
| Kapran, Y | 1 |
| Kuntsal, L | 1 |
| Purisa, S | 1 |
| Kemik, A | 1 |
| Bytsaĭ, AN | 1 |
| Ozdemir, MA | 1 |
| Işik, B | 1 |
| Patiroglu, T | 1 |
| Karakukcu, M | 1 |
| Mutlu, FT | 1 |
| Yilmaz, E | 1 |
| Unal, E | 1 |
| Raynaud, A | 1 |
| Novelli, L | 1 |
| Rovani, X | 1 |
| Carreres, T | 1 |
| Bourquelot, P | 1 |
| Hermelin, A | 1 |
| Angel, C | 1 |
| Beyssen, B | 1 |
| Arroja, B | 1 |
| Canhoto, M | 1 |
| Gonçalves, C | 1 |
| Silva, F | 1 |
| Cotrim, I | 1 |
| Vasconcelos, H | 1 |
| Vilela, M | 1 |
| Efe, E | 1 |
| Resim, S | 1 |
| Bulut, BB | 1 |
| Eren, M | 1 |
| Garipardic, M | 1 |
| Ozkan, F | 1 |
| Ozkan, KU | 1 |
| De Blanche, LE | 1 |
| Schmitz, ML | 1 |
| Johnson, CE | 1 |
| Best, TH | 1 |
| Drummond-Webb, JJ | 1 |
| De Paula, EV | 1 |
| Nascimento, MC | 1 |
| Ramos, CD | 1 |
| Ozelo, MC | 1 |
| Machado, TF | 1 |
| Guillaumon, AT | 1 |
| Arruda, VR | 1 |
| Annichino-Bizzacchi, JM | 1 |
| Diener, HC | 1 |
| Ringelstein, EB | 1 |
| von Kummer, R | 1 |
| Landgraf, H | 1 |
| Koppenhagen, K | 1 |
| Harenberg, J | 1 |
| Rektor, I | 1 |
| Csányi, A | 1 |
| Schneider, D | 1 |
| Klingelhöfer, J | 1 |
| Brom, J | 1 |
| Weidinger, G | 1 |
| Horio, T | 2 |
| Fujita, M | 3 |
| Tanaka, Y | 1 |
| Ishihara, M | 3 |
| Kishimoto, S | 3 |
| Nakamura, S | 3 |
| Hase, K | 1 |
| Maehara, T | 2 |
| van der Loo, B | 2 |
| Braun, J | 1 |
| Koppensteiner, R | 2 |
| Takikawa, M | 2 |
| Isoda, S | 1 |
| Sato, M | 1 |
| Nakayama, T | 1 |
| Yamamoto, Y | 1 |
| Shimizu, M | 1 |
| Hattori, H | 1 |
| Tachibana, S | 1 |
| Jivegård, L | 1 |
| Drott, C | 1 |
| Gelin, J | 1 |
| Groth, O | 1 |
| Hensäter, M | 1 |
| Jensen, N | 1 |
| Johansson, G | 1 |
| Konrad, P | 1 |
| Lindberg, B | 1 |
| Lindhagen, A | 1 |
| Lundqvist, B | 1 |
| Oden, A | 1 |
| Smith, L | 1 |
| Stenberg, B | 1 |
| Thornell, E | 1 |
| Wingren, U | 1 |
| Ortenwall, P | 1 |
| Spring, S | 1 |
| Amann-Vesti, BR | 1 |
| Meier, T | 1 |
| Pfammatter, T | 1 |
| Rousson, V | 1 |
| Banyai, M | 1 |
| Boulon, C | 1 |
| Maillet, A | 1 |
| Salaun, P | 1 |
| Skopinski, S | 1 |
| Constans, J | 1 |
2 reviews available for dalteparin and Ischemia
| Article | Year |
|---|---|
A case report of severe nasal ischemia from cold agglutinin disease and a novel treatment protocol including HBOT.
Topics: Administration, Topical; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Anticoagulants; Combined | 2019 |
Successful surgical management of a neonate with a saddle pulmonary embolus.
Topics: Anticoagulants; Arm; Cardiopulmonary Bypass; Ductus Arteriosus, Patent; Embolectomy; Enoxaparin; Fem | 2004 |
6 trials available for dalteparin and Ischemia
| Article | Year |
|---|---|
[The drug prevention of postoperative thromboses in patients with critical lower limb ischemia].
Topics: Anticoagulants; Aspirin; Critical Illness; Humans; Ischemia; Leg; Nadroparin; Platelet Aggregation I | 1999 |
[Prophylaxis of thrombotic complications in patients after reconstructive operations on the main arteries of the lower extremities, made for arteriosclerosis obliterans in a critical ischemia stage].
Topics: Aged; Anticoagulants; Arteriosclerosis Obliterans; Blood Coagulation; Enoxaparin; Female; Humans; Is | 2014 |
Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Heparin; Heparin, Low-Molecular-Wei | 2006 |
On-treatment function testing of platelets and long-term outcome of patients with peripheral arterial disease undergoing transluminal angioplasty.
Topics: Aged; Aged, 80 and over; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspir | 2011 |
Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial.
Topics: Aged; Dalteparin; Double-Blind Method; Drug Administration Schedule; Female; Fibrinolytic Agents; Fo | 2005 |
Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Dalteparin; Drug Therapy, Combinat | 2006 |
20 other studies available for dalteparin and Ischemia
| Article | Year |
|---|---|
[Digital ischemia in a gardener: is rose cutting a vascular risk factor?].
Topics: Alprostadil; Aneurysm; Anticoagulants; Aspirin; Diagnosis, Differential; Female; Finger Injuries; Fi | 2008 |
[Conus medullaris and cauda equina infarct in the course of thrombosis of deep veins of lower extremities].
Topics: Diabetes Mellitus, Type 2; Fibrinolytic Agents; Humans; Ischemia; Male; Middle Aged; Nadroparin; Pol | 2004 |
Cocaine-related peripheral vascular occlusive disease treated with iloprost in addition to anticoagulants and antibiotics.
Topics: Acute Disease; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anticoag | 2007 |
Prolonged transient hand ischaemia secondary to a penicillin skin test.
Topics: Aspirin; Calcium Channel Blockers; Cyanosis; Drug Hypersensitivity; Drug Therapy, Combination; Fibri | 2007 |
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascula | 2017 |
Changes in cardiac cells due to ticagrelor and enoxaparin in a rat ischemia/reperfusion model.
Topics: Animals; Apoptosis; Enoxaparin; Ischemia; Rats; Rats, Wistar; Reperfusion; Ticagrelor | 2021 |
A Patient-Tailored Approach to Management of Acute Limb Ischemia in Patients with COVID-19: A Case Series.
Topics: Adult; Aged; Arterial Occlusive Diseases; COVID-19; Enoxaparin; Female; Humans; Ischemia; Male; Midd | 2022 |
Impact of Enoxaparin +α Lipoic acid combination on oxidative stress, follicle development and apoptotic damage in ovarian ischemia reperfusion model.
Topics: Animals; Antioxidants; Biomarkers; Catalase; Enoxaparin; Female; Follicle Stimulating Hormone; Gluta | 2022 |
Effect of protection of enoxaparin against experimental ischemia/reperfusion injury in the rat ovary on in vitro fertilization outcomes.
Topics: Animals; Anti-Mullerian Hormone; Antioxidants; Enoxaparin; Female; Fertilization in Vitro; Humans; I | 2023 |
Headache in an HIV-Positive Patient: Dangerous Interaction.
Topics: Adult; Anti-HIV Agents; Anticoagulants; Cilostazol; Cytochrome P-450 CYP3A Inhibitors; Dideoxynucleo | 2018 |
Evaluation of the effects of hyperbaric oxygen treatment and enoxaparin on left colon anastomosis. An experimental study.
Topics: Anastomosis, Surgical; Animals; Anticoagulants; Collagen; Colon; Combined Modality Therapy; Disease | 2013 |
A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations.
Topics: Afibrinogenemia; Amputation, Surgical; Anemia; Anticoagulants; Blood Coagulation Tests; Disease Prog | 2015 |
Radiocephalic fistula complicated by distal ischemia: treatment by ulnar artery dilatation.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Catheters, Indwelling; Clopidogrel; Diabete | 2010 |
Acute mesenteric ischemia.
Topics: Abdominal Pain; Aged; Anticoagulants; Duodenum; Endoscopy, Digestive System; Enoxaparin; Gastric Muc | 2010 |
Successful treatment with enoxaparin of glans ischemia due to local anesthesia after circumcision.
Topics: Anesthesia, Local; Child; Circumcision, Male; Enoxaparin; Epinephrine; Fibrin Fibrinogen Degradation | 2013 |
Early in vivo anticoagulation inhibits the angiogenic response following hindlimb ischemia in a rodent model.
Topics: Animals; Anticoagulants; Blood Coagulation Factors; Disease Models, Animal; Enoxaparin; Hindlimb; Hi | 2006 |
Efficacy of fragmin/protamine microparticles containing fibroblast growth factor-2 (F/P MPs/FGF-2) to induce collateral vessels in a rabbit model of hindlimb ischemia.
Topics: Actins; Analysis of Variance; Angiogenesis Inducing Agents; Animals; Anticoagulants; Blood Pressure; | 2011 |
Attenuation of limb loss in an experimentally induced hindlimb ischemic model by fibroblast growth factor-2/fragmin/protamine microparticles as a delivery system.
Topics: Animals; Capillaries; Dalteparin; Disease Models, Animal; Drug Delivery Systems; Fibroblast Growth F | 2012 |
Effects of platelet-rich plasma-containing fragmin/protamine microparticles in enhancing endothelial and smooth muscle cell growth and inducing collateral vessels in a rabbit model of hindlimb ischemia.
Topics: Animals; Cells, Cultured; Dalteparin; Disease Models, Animal; Hindlimb; Ischemia; Male; Microspheres | 2013 |
Upper Limb Ischemia by Subclavian Artery Dissection after Osteopathic Manipulation.
Topics: Adult; Anticoagulants; Computed Tomography Angiography; Female; Hematoma; Heparin, Low-Molecular-Wei | 2018 |